Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated the characteristics and treatment outcomes of Hr-TB patients. Materials and methods: We retrospectively reviewed the medical records of Hr-TB patients treated at a South Korean tertiary referral hospital from January 2005 to December 2018. Results: We included 195 Hr-TB patients. 113 (57.9%) were male, and the median age was 56.6 [interquartile range, 40.2-68.6] years. Mutations in katG were the most frequent [54 (56.3%)], followed by those i...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
Funding: World Health Organization and Canadian Institutes of Health Research.Background: Isoniazid-...
Background Every year, over 1 million people develop isoniazid (INH) resistant tube...
Background: Drug resistance tuberculosis remains major public health problem worldwide. In India, th...
Isoniazid (INH) resistance is now the most common type of tuberculosis (TB) infection resistance wor...
Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to IN...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...
Abstract: Background and objectives: Isoniazid (INH) is one of the most potent anti-tuberculosis (TB...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
INTRODUCTION: The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the ...
BACKGROUND: Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. Howe...
AbstractIsoniazid mono-resistance is the most common first-line drug resistance in tuberculosis (TB)...
OBJECTIVE: Despite World Health Organization recommendations, concerns about promoting resistance ha...
Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to INH may increase...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
Funding: World Health Organization and Canadian Institutes of Health Research.Background: Isoniazid-...
Background Every year, over 1 million people develop isoniazid (INH) resistant tube...
Background: Drug resistance tuberculosis remains major public health problem worldwide. In India, th...
Isoniazid (INH) resistance is now the most common type of tuberculosis (TB) infection resistance wor...
Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to IN...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...
Abstract: Background and objectives: Isoniazid (INH) is one of the most potent anti-tuberculosis (TB...
INTRODUCTION: Consensus on the best treatment regimens for patients with isoniazid-resistant TB is l...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
INTRODUCTION: The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the ...
BACKGROUND: Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. Howe...
AbstractIsoniazid mono-resistance is the most common first-line drug resistance in tuberculosis (TB)...
OBJECTIVE: Despite World Health Organization recommendations, concerns about promoting resistance ha...
Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to INH may increase...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
Funding: World Health Organization and Canadian Institutes of Health Research.Background: Isoniazid-...
Background Every year, over 1 million people develop isoniazid (INH) resistant tube...